NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) E
Post# of 111
(Total Views: 205)
Posted On: 07/14/2022 4:33:39 PM
NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views
Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies. Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are a result of vaccination or an immune response to a virus; whether the immune response is likely to protect against future infection; and the possible ways to minimize the risk of a future infection,” a recent article explains. Aditxt recently announced its latest authorized channel partner, Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab. “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status. With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them,” said PMLS CEO Kevin Murdock of the partnership.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies. Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are a result of vaccination or an immune response to a virus; whether the immune response is likely to protect against future infection; and the possible ways to minimize the risk of a future infection,” a recent article explains. Aditxt recently announced its latest authorized channel partner, Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab. “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status. With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them,” said PMLS CEO Kevin Murdock of the partnership.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)ADiTx Therapeutics Inc. (ADTX) Stock Research Links
Scroll down for more posts ▼